Halozyme Therapeutics, Inc. (HALO) Stock Analysis
A live, multi-source view of Halozyme Therapeutics, Inc. (HALO): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy.
Sector: Healthcare · Industry: Biotechnology · United States · 423 employees · halozyme.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Halozyme Therapeutics, Inc. (HALO) had a market capitalization of $12.51B, a trailing P/E of 32.3 (forward 10.6) and a beta of 0.88; the shares traded in a 52-week range of $61.23 – $111.15 (45.3% over the year).
- Market cap
- $12.51B
- Enterprise value
- $14.45B
- Trailing P/E
- 32.3
- Forward P/E
- 10.6
- Price / book
- 87.52
- EPS (trailing)
- $3.41
- EPS (forward)
- $10.39
- Payout ratio
- 0.0%
- 52-week range
- $61.23 – $111.15
- 52-week change
- 45.3%
- Beta
- 0.88
- Average volume
- 2.0M
- Shares outstanding
- 113.5M
- Short % of float
- 16.90%
- Profit margin
- 24.9%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Halozyme Therapeutics, Inc. (HALO) last closed at $107.00 (the last completed close before that scan).
Technicals at the scan: RSI 62 (neutral territory), price +0.3% versus its 20-day average, 20-day versus 50-day average spread +15.3%, MACD histogram -1.00.
Sentiment inputs: 100% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 75/100.
Next scheduled company event: in 52 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of HALO; corporate insiders filed 0 buys and 12 sells (2 distinct filers, latest disclosure 2026-08-19). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Helen Torley (0B/11S), Bernadette Connaughton (0B/1S). Who is trading what
RapidTradeView pick record
HALO has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Halozyme Therapeutics, Inc. (HALO) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell HALO.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.